Home/CVS Health Corp./Q3-2025
▲ TAILWIND◑ DEPLOYING2025-12-09

CVS Health Corp. Q3-2025

Health Care · Health Care Services

Revenue
$400.0B
YoY Growth
—
EPS
$6.65
Gross Margin
—
Revenue by Segment
Aetna
—
CVS Caremark
—
CVS Pharmacy
—
Health Care Delivery
—

Operator Signal: TAILWIND

CVS Health is projecting mid-teens adjusted EPS CAGR through 2028, raised 2025 guidance across all metrics, and initiated 2026 guidance showing continued earnings acceleration. Aetna margin recovery and pharmacy-as-front-door strategy are the key drivers.

Founder Implication

If you're building health tech or digital health engagement tools, CVS is investing heavily in an open consumer engagement platform — that's either a distribution partner or a well-funded competitor coming for your market.

AI Intelligence

◑ DEPLOYING

CVS claims AI-driven solutions are already deployed across all four business segments and is building a new AI-native consumer engagement platform, but no specific revenue or efficiency metrics are attributed to AI.

Mentions: 3
◑ DEPLOYING
“CVS Health is building the platform as an artificial intelligence (AI)-native product.”— Press Release
◑ DEPLOYING
“The work builds on industry-leading AI driven solutions which are already deployed at Aetna, CVS Caremark, CVS Pharmacy, and the Health Care Delivery businesses”— Press Release
◑ DEPLOYING
“helping CVS Health to be more proactive in customer and consumer engagement, and driving efficiency in its operations”— Press Release

What They Actually Said

“CVS Health is committed to being the most trusted health care company in America. We are executing with discipline, strengthening our core businesses and delivering meaningful progress across our enterprise.”

— David Joyner, President and CEO
growth-signalguidance

“Our obligation is to ensure that CVS Health is best positioned to do the most good for the most people for the next 40 years.”

— David Joyner, President and CEO
growth-signal

“We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026. Our guidance philosophy is centered on providing credible and clear expectations with opportunities for outperformance.”

— Brian Newman, EVP and CFO
guidancegrowth-signal

Forward Guidance

RAISED
Raised 2025 total revenues guidance to at least $400.0 billion from at least $397.3 billion(full year)
RAISED
Raised 2025 Adjusted EPS guidance range to $6.60 to $6.70 from $6.55 to $6.65(full year)
RAISED
Raised 2025 adjusted operating income guidance range to $14.22B to $14.39B from $14.14B to $14.31B(full year)
MAINTAINED
Confirmed 2025 cash flow from operations guidance range of $7.5 billion to $8.0 billion(full year)
INITIATED
Initiated 2026 total revenues of at least $400.0 billion(full year)
INITIATED
Initiated 2026 Adjusted EPS guidance range of $7.00 to $7.20(full year)
INITIATED
Initiated 2026 adjusted operating income guidance range of $15.07B to $15.41B(full year)
INITIATED
Initiated 2026 cash flow from operations of at least $10.0 billion(full year)
INITIATED
Commits to mid-teens Adjusted EPS CAGR through 2028(long-term)

Who Ran This Call

DynamicCEO-Led Call
CEO Share71%
David JoynerPresident and CEO
CONFIDENT150 words
Brian NewmanEVP and CFO
CONFIDENT60 words
David Joyner: “do the most good for the most people for the next 40 years; most trusted health care company in America”
Brian Newman: “committed to doing what we say; credible and clear expectations with opportunities for outperformance”
Themes
guidance-raisedai-integrationdigital-transformationmargin-expansioncost-cutting